Pemetrexed-free vs. Pemetrexed-based Immunochemotherapy in Metastatic TTF-1 Negative Lung Adenocarcinoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE4
Clinical Trials Related to Pembrolizumab
Related studies linked through entity extraction aliases.
Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
A Phase II Study Evaluating the Efficacy and Safety of Pembrolizumab in Combination With Chemotherapy as Neoadjuvant Therapy for Triple-negative Breast Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
A Phase II Study of Neoadjuvant Sacituzumab Govitecan and Pembrolizumab Therapy for Immunochemotherapy-resistant Early-stage Triple-negative Breast Cancer (TNBC)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE1
Study of Healthy Donor FMT (hdFMT) and Pembrolizumab in Relapsed/Refractory (R/R) PD-L1 Positive NSCLC
- Status
- RECRUITING
- Phase
- PHASE2
A Study of Oral IRAK-4 Inhibitor CA-4948 in Combination With Pembrolizumab and Stereotactic Radiosurgery in Patients With Melanoma Brain Metastases
- Status
- SUSPENDED
- Phase
- PHASE1/PHASE2
Phase I/II Open Label Study Evaluating the Safety and Efficacy of Combining STAT3 Inhibition (TTI-101) With Anti-PD-1 Therapy (Pembrolizumab) in Patients With Recurrent or Metastatic (RM) Head and Neck Squamous Cell Carcinoma (HNSCC)
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
Double-blind Study to Evaluate the PK, Efficacy, Safety and Immunogenicity of MB12 Versus Keytruda® in Stage IV NSCLC
- Status
- RECRUITING
- Phase
- PHASE3
A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010/KEYVIBE-010)
- Status
- COMPLETED
- Phase
- PHASE3
Response to Immunotherapy in MMR-deficient Localized Colon Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Renal Retention in High Grade Upper Tract Urothelial Cancer
- Status
- RECRUITING
- Phase
- PHASE2
A Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid Tumors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Propranolol in Combination With Pembrolizumab and Standard Chemotherapy for the Treatment of Unresectable Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction Adenocarcinoma
- Status
- RECRUITING
- Phase
- PHASE2
A Study of HX008 Plus Transcatheter Arterial Chemoembolization (TACE) in the First-Line Treatment of Subjects With Stage IV (M1c) Melanoma That is Metastatic to the Liver
- Status
- UNKNOWN
- Phase
- PHASE3
Neoadjuvant TIL- and Response-Adapted Chemoimmunotherapy for TNBC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Feasibility Window Study of Pembrolizumab Prior to Second Evacuation for Post-molar Gestational Trophoblastic Neoplasia
- Status
- RECRUITING
- Phase
- PHASE2
A Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab in Combination With Mitotane in Patients With Advanced Adrenocortical Carcinoma
- Status
- TERMINATED
- Phase
- PHASE2
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
- Status
- RECRUITING
- Phase
- PHASE3